| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Hanke1
1 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford OX3 9DS, UK
2 Microbiology and Tumorbiology Center, Karolinska Institutet, Box 280, S–17177 Stockholm, Sweden
Correspondence
Tomas Hanke
thanke{at}molbiol.ox.ac.uk
A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime–boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.
Published ahead of print on 30 October 2002 as DOI 10.1099/vir.0.18738-0.
This article has been cited by other articles:
|
|
 |
|
  T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor J. Immunol., June 1, 2007; 178(11): 6761 - 6769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hanke, A. J. McMichael, and L. Dorrell Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction J. Gen. Virol., January 1, 2007; 88(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Larke, A. Murphy, C. Wirblich, D. Teoh, M. J. Estcourt, A. J. McMichael, P. Roy, and T. Hanke Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen J. Virol., December 1, 2005; 79(23): 14822 - 14833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gehrke, F. X. Heinz, N. L. Davis, and C. W. Mandl Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon J. Gen. Virol., April 1, 2005; 86(4): 1045 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. L. Nordstrom, M. N. E. Forsell, C. Barnfield, E. Bonin, T. Hanke, M. Sundstrom, G. B. Karlsson, and P. Liljestrom Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1 J. Gen. Virol., February 1, 2005; 86(2): 349 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Mollenkopf, L. Grode, J. Mattow, M. Stein, P. Mann, B. Knapp, J. Ulmer, and S. H. E. Kaufmann Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis Infect. Immun., November 1, 2004; 72(11): 6471 - 6479. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
